Table 2 Comparison of baseline characteristics and perioperative outcomes between patients with IVC interruption or not
Before Matching | After Matching | ||||||
|---|---|---|---|---|---|---|---|
Variables | All patients | Interruption of IVC | No interruption of IVC | P value | Interruption of IVC | No interruption of IVC | P value |
No. of patients, n (%) | 103 (100%) | 32 (31.1) | 71 (68.9) | – | 29 (50.0) | 29 (50.0) | – |
Gender, n (%) | 0.046 | 0.2 | |||||
Male | 77 (74.8) | 28 (87.5) | 49 (69.0) | 25 (86.2) | 21 (72.4) | ||
Female | 26 (25.2) | 4 (12.5) | 22 (31.0) | 4 (13.8) | 8 (27.6) | ||
Age at surgery, years | 60 (53–65) | 61 (53–67) | 60 (52–64) | 0.7 | 61 (53–67) | 62 (55–67) | 0.7 |
BMI, kg/m2 | 23.4 (21.1–26.0) | 24.1 (22.0–26.6) | 23.0 (20.5–25.8) | 0.078 | 23.9 (21.8–26.3) | 22.9 (20.7–25.4) | 0.3 |
Side, n (%) | 0.9 | 0.4 | |||||
Right | 75 (72.8) | 23 (71.9) | 52 (73.2) | 22 (75.9) | 19 (65.5) | ||
Left | 28 (27.2) | 9 (28.1) | 19 (26.8) | 7 (24.1) | 10 (34.5) | ||
Local symptoms | 103 (73.8) | 23 (71.9) | 53 (74.6) | 0.8 | 21 (72.4) | 18 (62.1) | 0.4 |
Systemic symptoms | 34 (33.0) | 11 (34.4) | 23 (32.4) | 0.8 | 10 (34.5) | 13 (44.8) | 0.4 |
Tumor diameter, cm | 8.3(6.4–10.5) | 7.7 (5.6–10.3) | 8.4 (6.6–10.9) | 0.3 | 7.7 (5.6–10.2) | 7.0 (6.3–9.0) | 0.8 |
ASA score, n (%) | 0.027 | 0.6 | |||||
1 | 5 (4.9) | 0 (0.0) | 5 (7.0) | 0 (0.0) | 0 (0.0) | ||
2 | 77 (74.7) | 21 (65.6) | 56 (78.9) | 19 (65.5) | 21 (72.4) | ||
3 | 21 (20.4) | 11 (34.4) | 10 (14.1) | 10 (34.5) | 8 (27.6) | ||
VTT level, n (%) | 0.077 | 0.5 | |||||
II | 67 (65.0) | 18 (56.3) | 49 (69.0) | 17 (58.6) | 17 (58.6) | ||
III | 19 (18.5) | 10 (31.2) | 9 (12.7) | 8 (27.6) | 5 (17.2) | ||
IV | 17 (16.5) | 4 (12.5) | 13 (18.3) | 4 (13.8) | 7 (24.1) | ||
Preoperative lab values | |||||||
Creatinine, μmmol/L | 92 (81–112) | 110 (92–116) | 89 (76–106) | 0.002 | 110 (91–115) | 91 (80–115) | 0.072 |
Hemoglobin, g/L | 119 (107–126) | 117 (102–123) | 120 (109–133) | 0.15 | 118 (103–124) | 111 (90–126) | 0.7 |
Operative time, min | 387 (312–476) | 424 (375–508) | 362 (288–471) | 0.021 | 426 (375–507) | 387 (300–502) | 0.3 |
Estimated blood loss, ml | 1500 (500–3000) | 2450 (1350–4000) | 1000 (300–2800) | 0.001 | 2400 (1350–4000) | 2000 (800–3000) | 0.2 |
Blood transfusion, ml | 1200 (0–2000) | 1600 (1200–2700) | 400 (0–1600) | < 0.001 | 1600 (1200–2600) | 1200 (400–2000) | 0.087 |
Serum Creatinine at 7 days postoperatively, μmmol/L | 100 (81–121) | 100 (86–119) | 101 (79–123) | 0.8 | 99 (87–118) | 103 (81–117) | 0.8 |
Postoperative hospital stay, days | 10 (8–14) | 13 (11–14) | 9 (7–14) | 0.004 | 13 (10–14) | 9 (8–14) | 0.022 |
Overall complication, n (%) | 60 (58.3) | 26 (81.3) | 34 (47.9) | 0.001 | 23 (79.3) | 15 (51.7) | 0.027 |
Major complication, n (%) | 14 (13.7) | 5 (18.8) | 9 (12.7) | 0.7 | 5 (17.2) | 3 (10.3) | 0.4 |